



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

09 Mar 2020 (#11)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Important Notice

- NIH is migrating from Forms-E to the **new Forms-F application package**. All submissions on or after 25 May 2020 must use FORMS-F application forms and instructions. See the [How to Apply - Application Guide](#)
- Where Can I Find [Diversity Related Funding Opportunity Announcements?](#)
- **NOT-DA-20-020: Notice of Special Interest (NOSI): Going Global: Using Gene Network Analyses to Understand the Etiology of SUD.** The purpose of this NOSI is to encourage applications that explore and/or test the role of gene networks in substance use disorders (SUD) through the development, optimization, and/or implementation of multilevel computational, bioinformatics, statistical and/or analytical approaches that integrate at least two levels of data e.g. genomic, epigenomic, chromatin, environmental, etc.
- **NOT-AA-20-004** Notice of Intent to Publish a Funding Opportunity Announcement for **Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD)** Exploratory/Developmental Research Projects (UH2 Cooperative Agreement, Clinical Trial Optional. National Institute on Alcohol Abuse and Alcoholism (NIAAA) intends to promote a new initiative on developing effective diagnosis/screening, interventions and treatment approaches for Fetal Alcohol Spectrum Disorders (FASD). Awardees will be encouraged to establish a collaborative relationship with the NIAAA-supported CIFASD consortium. This Notice is being provided to allow potential applicants sufficient time to develop responsive projects. Budget: \$175,000 in direct costs.
- **NOT-DA-20-039** Notice of Special Interest (NOSI): **Effects of Cannabis Use and Cannabinoids on the Developing Brain.** The purpose of this Notice is to encourage investigators to submit grant applications to the National Institute on Drug Abuse (NIDA) to study the effects of cannabis and cannabinoid exposure on the developing brain, from pre-, peri-, and post-natal development through young adulthood in humans and using animal models.
- University of Washington, Seattle, WA Department of Global Health is accepting applications for the [Implementation Science in Global Health Summer Institute](#). Some full and partial tuition scholarships available for Non-OECD country participants. **Application deadline: May 22, 2020.** This intensive course will be of interest to researchers, policy makers, funders, and practitioners working in low and middle income settings who are interested in either gaining an intensive introduction or advanced training in implementation science. **Week 1:** August 24-28, 2020 (Didactic training in two tracks: Fundamentals of Implementation Science or Advanced Training in Implementation Science). **Week 2:** (Optional): August 31-September 04, 2020 Mentored protocol development for a subset of participants in week 1).
- **NOT-OD-20-074:** The National Institutes of Health (NIH) Sexual & Gender Minority Research Office (SGMRO) Announces Regional Workshop on Sexual and Gender Minority (SGM)-Related Health Research. [The Sexual & Gender Minority Research Office \(SGMRO\)](#) coordinates Sexual and Gender Minority (SGM)-related research and activities by working directly with NIH Institutes, Centers, and Offices. The Office was officially established in September 2015 within the NIH Division of Program Coordination, Planning, and Strategic Initiatives. The Regional Workshop is being held on April 2, 2020, in collaboration with Equitas Health and The Ohio State University in Columbus, Ohio. Visit <https://dpcpsi.nih.gov/sgmro/regionalworkshop>. The workshop is free to attend but space is limited.

- **Next Generation Researchers Initiative:** NIH recommends “special funding consideration for “at-risk” investigators. These are researchers who developed meritorious applications, who would not have significant NIH research funding if the application under consideration is not awarded. NIH plans to draw more attention this year, both inside and outside NIH, to outcomes for at-risk investigators, to ensure those submitting meritorious ideas to NIH are not lost to the system.

1. Integrated Preclinical / Clinical AIDS Vaccine Development Program (IPCAVD) (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-20-120](#)

Type: U19

Application Due Date: July 28, 2020; March 9, 2021; March 9, 2022 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of the Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) Funding Opportunity Announcement (FOA) is to facilitate the translation of vaccine candidates into early clinical testing. The IPCAVD program is designed to enable a multi-disciplinary team to complete necessary steps from final down-selection of an advanced HIV-1 vaccine candidate through regulatory submissions needed for clinical trial(s). These steps include technology transfer, process development, optimization studies, assay development and qualification, analytical testing, Current Good Manufacturing Practice (CGMP) manufacture, quality assurance oversight, safety testing, product release and storage, drug substance and drug product stability testing program, IND-enabling studies, and regulatory submissions. This FOA will not provide funds for conducting the clinical studies; applicants are encouraged to collaborate with NIAID-supported clinical trial networks or to develop other relationships to support the clinical studies.

Budget: NIH intends to fund an estimate of 1-2 awards, corresponding to a total of \$5.0 million, for fiscal year 2021. Future year amounts will depend on annual appropriations. Application budgets are limited to \$3 million direct costs per year. Application budgets need to reflect the actual needs of the proposed Program. The project period is five years

2. Harnessing Natural Killer (NK) Cells to Prevent, Control, or Eradicate HIV (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AI-20-016](#)

Type: R01

Application Due Date: July 28, 2020. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) will support basic, translational, and clinical research to improve the understanding of the effector or immunoregulatory potentials of NK cells for HIV prevention, control and/or eradication.

Budget: NIAID and partner components intend to commit an estimated total of \$3,250,000 in FY21 to fund 4-6 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

3. Research Towards Developing a Cure for HBV in HIV/HBV Co-Infection (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAS-20-121](#)

Type: R21

Application Due Date: [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for support of innovative basic, translational, and clinical research to identify and address the challenges to achieving hepatitis B virus (HBV) cure in the presence of human immunodeficiency virus (HIV).

Budget: NIH intends to fund an estimate of 6-8 awards, corresponding to a total of \$2.0M, for fiscal year 2021. Future year amounts will depend on annual appropriations. The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

4. Advancing HIV/AIDS Research within the Mission of the NIDCD (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-20-123](#)
[PAR-20-127](#)

Type: R21
R01

Application Due Date: [Standard AIDS dates](#). Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to stimulate HIV/AIDS research within the scientific mission areas of the National Institute on Deafness and Other Communications Disorders ([NIDCD](#)). Applications should address high priority HIV/AIDS research outlined by the NIH Office of AIDS Research (OAR) [<https://www.oar.nih.gov/hiv-policy-and-research/research-priorities>] in the areas of hearing, balance, taste, smell, voice, speech, and language. For applications with a clinical trial, only low risk clinical trials will be supported.

Budget: **R21:** NIDCD intends to fund an estimate of 1-2 awards, corresponding to a total of \$200,000 for fiscal year 2021. The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. The total project period may not exceed 2 years. **R01:** NIDCD intends to fund an estimate of 1-2 awards, corresponding to a total of \$600,000 for fiscal year 2021. Application budgets are limited to no more than \$499,999 in direct costs in any year and need to reflect the actual needs of the proposed project.

5. Advancing Vaccine Science to Improve Tuberculosis Treatment Outcomes for People Living With or Without HIV (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AI-20-010](#)

Type: R01

Application Due Date: July 28, 2020. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement is to invite applications for innovative clinical, and preclinical/translational research to develop therapeutic vaccine strategies to improve treatment outcomes of active tuberculosis (TB) in the presence or absence of HIV co-infection.

Budget: NIAID intends to commit \$4 million in FY 2021 to fund 2-3 awards. Application budgets are limited to \$800,000 in direct costs per year, but also need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

6. Multidisciplinary Studies to Improve Understanding of Influenza Transmission (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AI-20-008](#)

Type: U19

Application Due Date: June 23, 2020 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for collaborative, multidisciplinary research to comprehensively investigate the dynamics and drivers of influenza transmission between humans. This FOA will support research to: (1) improve detection and sampling of influenza viral particles from the air; (2) develop novel assays to assess viability and infectivity of influenza viral particles collected from the air; and (3) comprehensively evaluate the contribution of viral, host, physical, and environmental factors to influenza transmission between humans.

Budget: NIAID intends to commit \$6 million in FY2021 to fund up to 3 awards. Recommended budgets of up to \$2 million in direct costs per year may be requested. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

7. Rational Design of Vaccines Against Hepatitis C Virus (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AI-20-019](#)

Type: U19

Application Due Date: June 15, 2020. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to support novel strategies for the rational design of vaccines against hepatitis C virus (HCV), to assess the vaccines for their ability to induce protective immune responses, and to select candidates for preclinical development and clinical testing. To this end, it will be critical to advance knowledge of the structural basis for broad immunological protection, and to elucidate correlates of HCV protection by leveraging samples from existing human cohorts and vaccine studies. This information will serve as a guide for the construction of new and improved candidate prophylactic HCV vaccines that will be assessed for immunogenicity and efficacy in appropriate animal models.

Budget: NIAID intends to commit \$8,000,000 in FY 2021 to fund 3-4 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed research program should determine the project period. The maximum project period is 5 years.

8. Exploring the Roles of Biomolecular Condensates (BMCs) in HIV replication, latency, or pathogenesis in the context of substance use disorders (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-DA-21-004](#)

Type: R21/R33

Application Due Date: July 20, 2020. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: To support research projects exploring the roles of biomolecular condensates (BMCs) and their regulators in processes relevant to HIV/SIV infection, replication, latency, or pathogenesis in the context of substance use disorders. These processes could include studies exploring BMC involvement in HIV infection, HIV replication (including viral gene expression), HIV latency formation or maintenance (including chromatin structure), or HIV pathogenesis (including neurodegenerative processes). Studies could also include investigation of roles for BMCs or their regulators on host cell functions in the context of HIV infection, antiretroviral therapy, and/or exposure to addictive substances.

Budget: NIDA intends to commit \$1.2M in FY 2021 to fund 5-6 awards. Applicants may request up to \$125k direct costs for each year of the R21 phase and up to \$250k direct costs for each year of the R33 phase. The proposed R21 project period may not exceed two years, while the proposed R33 project period may not exceed three years.

9. BRAIN Initiative: Standards to Define Experiments Related to the BRAIN Initiative (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-MH-20-128](#)

Type: R01

Application Due Date: September 3, 2020 and September 2, 2021. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) solicits applications to develop standards that describe experimental protocols that are being conducted as part of the BRAIN Initiative. It is expected that applications will solicit community input at all stages of the process. It is recommended that the first step of standard development will involve sharing data between different key groups in the experimental community in order to ensure that the developing standard will encompass the data collection efforts of those groups. The developed standard is expected to be broadly disseminated for use and widely available.

Budget: Issuing IC and partner components intend to commit an estimated total of \$3 million to fund 2-3 awards in FY 21. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 2 years.

10. International Research Ethics Education and Curriculum Development Award (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-19-244](#)

Type: R25

Application Due Date: June 4, 2020, June 4, 2021. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this R25 program is to support educational activities that foster a better understanding of biomedical, behavioral and clinical research and its implications.

- Courses for Skills Development
- Mentoring Activities
- Curriculum or Methods Development

The goal of this initiative is to support educational activities that foster a better understanding of the ethics of international biomedical, behavioral and clinical research and enhance the application of research ethics principles in low- and middle-income countries (LMICs). This program aims to increase the number of LMIC research intensive institutions that can provide advanced education in international research ethics. Education programs supported by this initiative will equip scientists, health professionals and academics in these countries with in-depth knowledge of the ethical principles, processes and policies related to international clinical and public health research. Programs should be designed to strengthen the critical competencies needed to provide research ethics education, ethical review leadership and expert consultation to LMIC researchers, their institutions, governments and international research organizations. To accomplish this goal, this FOA will support innovative LMIC masters level research ethics education programs proposing integrated activities to develop curriculum, courses for skills development, including practicum experiences, and creative mentoring approaches.

Budget: Applications may request up to \$230,000 direct costs per year. The total project period may not exceed 5 years. This R25 program is not intended as a substitute for an institutional research training program (e.g. D43). With sufficient justification, applicants may request costs to support either part-time or full time participants in the proposed education program. Applicants may request support for LMIC participant travel to research ethics conferences when giving presentations.

11. Planning Grant for Fogarty HIV Research Training Program for Low- and Middle-Income Country Institutions (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-19-284](#)

Type: D71

Application Due Date: August 20, 2020; August 20, 2021. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The Fogarty HIV Research Training Program supports research training that strengthens HIV research capacity of institutions in low-and middle-income countries (LMICs). This FOA offers an opportunity for LMIC institutions to submit a planning grant application to prepare to participate in the Fogarty HIV Research Training Program.

These applications must propose a plan to develop a research training program and the subsequent application that will be submitted in response to the companion D43 FOA ([PAR-19-283](#)). The planned research training program should strengthen research capacity in a defined high priority HIV scientific area ([NOT-OD-15-137](#)) at an LMIC institution(s).

Budget: Application budgets are limited to \$28,000 direct costs per year exclusive of consortium indirect costs. The maximum project period is 2 years.

12. Rational Design of Vaccines Against Hepatitis C Virus (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AI-20-019](#)

Type: U19

Application Due Date: June 15, 2020. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to support novel strategies for the rational design of vaccines against hepatitis C virus (HCV), to assess the vaccines for their ability to induce protective immune responses, and to select candidates for preclinical development and clinical testing. To this end, it will be critical to advance knowledge of the structural basis for broad immunological protection, and to elucidate correlates of HCV protection by leveraging samples from existing human cohorts and vaccine studies. This information will serve as a guide for the construction of new and improved candidate prophylactic HCV vaccines that will be assessed for immunogenicity and efficacy in appropriate animal models.

Budget: NIAID intends to commit \$8,000,000 in FY 2021 to fund 3-4 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed research program should determine the project period. The maximum project period is 5 years.

13. Multidisciplinary Studies to Improve Understanding of Influenza Transmission (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AI-20-008](#)

Type: U19

Application Due Date: June 23, 2020. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for collaborative, multidisciplinary research to comprehensively investigate the dynamics and drivers of influenza transmission between humans. This FOA will support research to: (1) improve detection and sampling of influenza viral particles from the air; (2) develop novel assays to assess viability and infectivity of influenza viral particles collected from the air; and (3) comprehensively evaluate the contribution of viral, host, physical, and environmental factors to influenza transmission between humans.

Budget: NIAID intends to commit \$6 million in FY2021 to fund up to 3 awards. Recommended budgets of up to \$2 million in direct costs per year may be requested. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

14. Fogarty HIV Research Training Program for Low-and Middle-Income Country Institutions (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-19-283](#)

Type: D43

Application Due Date: August 20, 2020; August 20, 2021. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications for research training programs to strengthen the scientific capacity of institutions in low- and middle-income countries (LMICs) to conduct HIV research relevant to the evolving HIV epidemic in their country. This FOA can support training for conducting research in a broad range of HIV research areas across HIV prevention, treatment, care, and quality of life continuum. This includes basic, epidemiologic, clinical, behavioral and social sciences, community-based, implementation, operations, health services, and health systems research. Cross-disciplinary research as well as HIV associated comorbidities and coinfections affecting the HIV epidemic will be supported under this FOA. An application should focus the proposed training program to strengthen research capacity in a defined HIV scientific area at a specific LMIC institution and collaborating LMIC partner institutions. This FOA allows qualified Trainees to serve as the lead investigator of an independent clinical trial; or to propose a separate ancillary study to an existing trial under the mentorship of an appropriate clinical researcher or to gain research experience in a clinical trial led by another investigator, as part of their research and career development.

Budget: Application budgets are limited to \$280,000 in direct costs per year exclusive of consortium indirect costs. The maximum project period is 5 years. Awards may provide stipends as a subsistence allowance to help defray living expenses during the research training experience for medium-and long-term trainees. Awards can contribute to the cost of tuition and fees. Awards may support travel for trainees to participate in appropriate training experiences at other institutions or to attend scientific meetings and workshops that the training program determines to be necessary for the individual's research training.

15. Exploring the Roles of Biomolecular Condensates (BMCs) in HIV replication, latency, or pathogenesis in the context of substance use disorders (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-DA-21-004](#)

Type: R21/R33

Application Due Date: July 20, 2020. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: To support research projects exploring the roles of biomolecular condensates (BMCs) and their regulators in processes relevant to HIV/SIV infection, replication, latency, or pathogenesis in the context of substance use disorders. These processes could include studies exploring BMC involvement in HIV infection, HIV replication (including viral gene expression), HIV latency formation or maintenance (including chromatin structure), or HIV pathogenesis (including neurodegenerative processes). Studies could also include investigation of roles for BMCs or their regulators on host cell functions in the context of HIV infection, anti-retroviral therapy, and/or exposure to addictive substances.

Budget: National Institute on Drug Abuse (NIDA) intends to commit \$1.2M in FY 2021 to fund 5-6 awards. Applicants may request up to \$125k direct costs for each year of the R21 phase and up to \$250k direct costs for each year of the R33 phase. The proposed R21 project period may not exceed two years, while the proposed R33 project period may not exceed three years.

16. BRAIN Initiative: Standards to Define Experiments Related to the BRAIN Initiative (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-MH-20-128](#)

Type: R01

Application Due Date: September 3, 2020 and September 2, 2021. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) solicits applications to develop standards that describe experimental protocols that are being conducted as part of the BRAIN Initiative. It is expected that applications will solicit community input at all stages of the process. It is recommended that the first step of standard development will involve sharing data between different key groups in the experimental community in order to ensure that the developing standard will encompass the data collection efforts of those groups. The developed standard is expected to be broadly disseminated for use and widely available.

Budget: Issuing IC and partner components intend to commit an estimated total of \$3 million to fund 2-3 awards in FY 21. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 2 years.

17. International Bioethics Research Training Program (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-19-243](#)

Type: D43

Application Due Date: June 4, 2020, June 4, 2021. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The overall goal of this initiative is to support the development of a sustainable critical mass of bioethics scholars in low and middle-income country (LMIC) research intensive institutions with the capabilities to conduct original empirical or conceptual ethics research that addresses challenging issues in health research and research policy in these countries as well as provide research ethics leadership to their institutions, governments and international research organizations. FIC will support LMIC-U.S. collaborative institutional bioethics doctoral and postdoctoral research training programs that incorporate didactic, mentored research and training components to prepare multiple individuals with ethics expertise for positions of scholarship and leadership in health research institutions in the LMIC. This Funding Opportunity Announcement (FOA) allows support of trainees as the lead investigator of an independent clinical trial; or a separate ancillary study to an existing trial; or to gain research experience in a clinical trial led by another investigator, as part of their research and career development.

Budget: Applicants may request up to \$230,000 direct costs per year. The total project period for an application submitted in response to this funding opportunity may not exceed 5 years. Awards may provide stipends as a subsistence allowance to help defray living expenses during the research training experience. Awards can contribute to the cost of tuition and fees. Trainee travel to attend scientific meetings and workshops that the institution determines to be necessary for the individual's research training experience is an allowable trainee expense for predoctoral and postdoctoral trainees.

**Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences, Stellenbosch University**
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)
Stellenbosch University
2038 Wilcocks Building, Ryneveld Street
Enquiries: *Lizél*
e: lizelk@sun.ac.za | t: +27 21 808 2105